Hearing Following Prolonged and Delayed Ganciclovir Treatment in a Murine Cytomegalovirus Model
The Laryngoscope · 2024
DOI: 10.1002/lary.30860 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, 2024. Verfasst von Katrina Hillam und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, University of Utah, Salt Lake City, Utah, U.S.A. Hauptthemen laut MEDLINE: Muromegalovirus, Cytomegalovirus Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Objective
Compare hearing outcomes utilizing standard, prolonged and delayed ganciclovir (GCV) therapy in a murine model of cytomegalovirus (CMV).
Methods
BALB/c mice were inoculated with mouse cytomegalovirus (mCMV) or saline via intracerebral injection on postnatal day 3 (p3). Intraperitoneal GCV or saline was administered at 12 h intervals for the duration of the standard (p3‐p17), delayed (p30‐p44), or prolonged treatment windows (p3‐p31). Auditory thresholds were assessed using distortion product otoacoustic emission (DPOAE) and auditory brainstem response (ABR) testing at 4, 6, and 8 weeks of age. Blood and tissue samples were harvested from mice on p17 and p37 one hour after GCV administration, and their concentrations were assessed via liquid chromatography‐mass spectrometry.
Results
A delayed course of GCV improved ABR but not DPOAE thresholds in mCMV‐infected mice. A prolonged course of GCV did not provide better hearing thresholds than those administered standard treatment. The average GCV concentration in all 17‐day‐old mice tissue was significantly higher than those in older 37‐day‐old mice.
Conclusion
Delayed GCV treatment provided a hearing benefit on ABR over untreated mCMV infected mice. Prolonged CGV administration showed no benefit compared to a shorter duration GCV treatment. GCV drug concentrations both systemically and in the cochlea are much lower in older mice. These results have potential implications for the clinical management of cCMV infected children. Level of Evidence NA Laryngoscope , 134:433–438, 2024
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, University of Utah, Salt Lake City, Utah, U.S.A.
- Department of Otolaryngology, State University of New York Downstate Medical Center, Stony Brook, New York, U.S.A.
- Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.
- Department of Surgery, University of Utah, Salt Lake City, Utah, U.S.A.
- University of Utah Center for Human Toxicology and Department of Pharmacology and Toxicology, Salt Lake City, Utah, U.S.A.
ORCID-Profile: Emily Huang, Albert H Park
Zitieren
APA
Hillam, K., Suarez, D., Nielson, C., Traxler, A., Sommer, E., Winslow, A., Holley, A., Huang, E., Hughes, M., Firpo, M. A., Rower, J., & Park, A. H. (2024). Hearing Following Prolonged and Delayed Ganciclovir Treatment in a Murine Cytomegalovirus Model. The Laryngoscope. https://doi.org/10.1002/lary.30860
Vancouver
Hillam K, Suarez D, Nielson C, Traxler A, Sommer E, Winslow A, et al. Hearing Following Prolonged and Delayed Ganciclovir Treatment in a Murine Cytomegalovirus Model. The Laryngoscope. 2024. doi:10.1002/lary.30860
BibTeX
@article{Hillam2024,
author = {Hillam, Katrina and Suarez, Daniel and Nielson, Christopher and Traxler, Abigail and Sommer, Elizabeth and Winslow, Anna and Holley, Anna and Huang, Emily and Hughes, Maura and Firpo, Matthew A and Rower, Joseph and Park, Albert H},
title = {Hearing Following Prolonged and Delayed Ganciclovir Treatment in a Murine Cytomegalovirus Model},
journal = {The Laryngoscope},
year = {2024},
doi = {10.1002/lary.30860}
}
EUVIMED